NDAORALTABLETPriority Review
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRINSUPRI (brensocatib) is an oral small-molecule tablet approved by the FDA on August 12, 2025, currently in launch phase. The mechanism of action and specific indication have not been disclosed in available data. Patient population and therapeutic area require access to full prescribing information.
Growth13.7 years to LOE
Recent launch phase with minimal competitive pressure creates significant opportunity for rapid team expansion and brand-building initiatives across commercial, medical affairs, and operations functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Started Dec 2024
214 enrolled
Hidradenitis Suppurativa
A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
Started Apr 2024
24 enrolled
Healthy Participants
A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
Started Dec 2023
20 enrolled
Healthy Volunteers
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Started Oct 2023
288 enrolled
Chronic Rhinosinusitis Without Nasal Polyps
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
Started Jul 2023
22 enrolled
Healthy Volunteers
Worked on BRINSUPRI at Insmed? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.